Introduction: Vancomycin administration in individuals with hematological malignancy or neutropenia is associated with a suboptimal trough concentration. Nonetheless, most studies did not distinguish whether low vancomycin trough concentrations were due to hematological malignancies or neutropenia. This study aimed to determine the association between types of hematological malignancy and febrile neutropenia with low vancomycin concentrations. Methods: The present retrospective chart review study was conducted by using clinical data adopted from computerized physician order entries (BestCare®) for all of the patients who received intravenous vancomycin treatment between January 2017 and December 2020 at King Abdulaziz Medical City in Jeddah. Results: Out of the 296 patients, 217 were included. There was no significant association between the type of hematological malignancy and the incidence of a low trough concentration (p > 0.05), while a significant association between febrile neutropenia and the incidence of a low trough concentration was observed (p < 0.05). Furthermore, the predictors for a low trough among febrile neutropenic patients were creatinine clearance (CrCI) and a low albumin concentration. In addition, there was a significant association between febrile neutropenia and augmented renal clearance (p < 0.05). Conclusions: The findings of this study conclude that febrile neutropenia is associated with low vancomycin concentrations. Interestingly, augmented renal clearance was observed in most of the febrile neutropenia patients with a significant association, which is considered the main driver for a low trough in neutropenic patients.
Sickle cell disease (SCD) affects millions globally, with approximately 0.26% of the Saudi population impacted. Despite standard treatments, patients frequently experience vaso-occlusive crises (VOCs). This retrospective observational study evaluated the real-world effectiveness of L-glutamine (Endari®) in reducing SCD-related complications in the Saudi population, where data remain limited. Patients aged five and older who received L-glutamine from June 2019 to June 2023 were included. The primary endpoint was VOC frequency through week 48. Descriptive statistics and paired t-tests compared outcomes before and after treatment. Fifteen patients (median age 12 years, 53% female) met the inclusion criteria; all were on maximum tolerated hydroxyurea. Eleven completed 48 weeks, showing a median VOC reduction from 4 to 3 (p = 0.44). Hospital stay duration remained unchanged (median 7 days, p = 0.72). Laboratory parameters were largely stable, except for a 61.9% increase in reticulocyte count (p = 0.03). The estimated annual treatment cost exceeded SAR 2 million (USD ~547,840). L-glutamine did not produce statistically significant improvements in VOC frequency, though numerical trends were observed. Given the small sample size and limited statistical power, the findings are exploratory. Larger, well-powered, multicenter studies are needed to confirm L-glutamine’s potential benefits in this population.
Background: Biosimilar versions of Rituximab have the same safety profile and efficacy as the reference prod-uct across all indications for which it is approved based on the extrapolation principle. Our organization had replaced IV Rituximab (Mabthera) with IV Rituximab (Truxima-Biosimilar) in 2021. Hence, practice was changed to give first cycles of IV Rituximab (Truxima-Biosimilar) instead of Rituximab (Mabthera) and if first cycle was completed without severe infusion related reactions (IRRs) then subsequent cycles were given with subcutaneous Rituximab as per institutional guidelines. There is no evidence of the safety of this practice. Therefore, we decided to evaluate the safety of this practice in retrospective fashion. Objective: The primary objective was to assess IRRs after using Rituximab (Truxima-Biosimilar) instead of Rituximab (Mabthera) IV in-jection in the first cycle followed by subcutaneous rituximab in subsequent cycles. While secondary objective was to determine the overall response rate (ORR). Methods: A retrospective observational study was con-ducted at Princess Nourah Oncology Center (PNOC) in Jeddah, Saudi Arabia. Results: Seventy-one patients were reviewed, and 35 patients met the eligibility criteria. Only one (3%) out of 35 patients developed IRR. However, it was only grade 1 IRR as per CTC.AE V5 and this patient was able to complete the rest of Rituxi-mab infusion intravenously (IV) in the first cycle successfully. Hence all patients transitioned from IV Rituxi-mab biosimilar to subcutaneous (SC) Rituximab Mabthera. Conclusions: We conclude from our real-world evidence study that transition from IV Rituximab biosimilar to SC Rituximab Mabthera is well tolerated and safe practice and confirms the extrapolation principle of biosimilars.